• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

94.65 -0.82 (-0.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,117,138
Open 94.95
Bid (Size) 92.30 (100)
Ask (Size) 95.50 (200)
Prev. Close 95.47
Today's Range 93.63 - 95.20
52wk Range 57.77 - 112.29
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Incyte (INCY) Q4 2024 Earnings Transcript ↗
April 22, 2026
Incyte (INCY) Q4 2024 Earnings Transcript 
Via The Motley Fool
Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case ↗
April 20, 2026
Via Chartmill

Performance

YTD
-6.7%
-6.7%
1 Month
+2.6%
+2.6%
3 Month
-7.7%
-7.7%
6 Month
+1.7%
+1.7%
1 Year
+60.0%
+60.0%

More News

Read More
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup ↗
April 11, 2026
Via Chartmill
News headline image
Incyte to Report First Quarter Financial Results
April 09, 2026
From Incyte
Via Business Wire
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals ↗
February 21, 2026
Via Chartmill
News headline image
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 07, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
April 02, 2026
From Adagene Inc.
Via GlobeNewswire
News headline image
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
March 29, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 28, 2026
From Incyte
Via Business Wire
News headline image
Incyte Announces Executive Leadership Appointments
March 25, 2026
From Incyte
Via Business Wire
News headline image
2 Growth Stocks with Explosive Upside and 1 We Avoid
March 23, 2026
Via StockStory
News headline image
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 20, 2026
From Incyte
Via Business Wire
News headline image
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
March 16, 2026
Via StockStory
News headline image
2 Value Stocks to Consider Right Now and 1 We Ignore
March 13, 2026
Via StockStory
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
March 11, 2026
Via StockStory
Topics Stocks
News headline image
Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗
March 06, 2026
Via Stocktwits
News headline image
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
March 06, 2026
From Incyte
Via Business Wire
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
March 04, 2026
Via StockStory
News headline image
3 S&P 500 Stocks to Target This Week
February 23, 2026
Via StockStory
Topics Stocks
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Question
February 18, 2026
Via StockStory
News headline image
Registration Momentum Builds Across the Oncology Pipeline
February 17, 2026
From USA News Group
Via GlobeNewswire
News headline image
Incyte to Present at Upcoming Investor Conferences
February 17, 2026
From Incyte
Via Business Wire
News headline image
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call
February 17, 2026
Via StockStory
Topics Earnings

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 94.65
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 04/24/26 04:00 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 21.05B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 21B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap